Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
- Conditions
- Painful Diabetic NeuropathyDiabetic Neuropathy, Painful
- Interventions
- Genetic: Long-Term Follow-Up of Patients who Received Engensis (VM202)Drug: Long-Term Follow-Up of Patients who Received Placebo
- Registration Number
- NCT04055090
- Lead Sponsor
- Helixmith Co., Ltd.
- Brief Summary
The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy.
All subjects still in follow-up for the VMDN-003 study or who have completed the Day 270 visit within the prior 90 days will be approached to enroll in the long-term safety extension study.
- Detailed Description
In the phase III VMDN-003 study, subjects received 2 treatments of either Engensis (VM202) or placebo administered as intramuscular injections into bilateral calves on Days 0 and 14, and Days 90 and 104. Primary efficacy was evaluated 90 days following the first injection. The growth potential for Hepatocyte Growth Factor make long-term follow-up important both for safety and efficacy: in order for Engensis to be a candidate for chronic treatment of Painful Diabetic Peripheral Neuropathy, it must be demonstrated not to induce unexpected adverse events with repeated dosing; and the potential for reversal or stabilization of diabetic neuropathy using only one or two treatments of Engensis may make it especially attractive compared to current treatments which must be taken daily for the duration of the disease. A safety extension to the VMDN-003 study is therefore warranted.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 101
- Were randomized and dosed in the VMDN-003 study
- Received all intramuscular injections of study drug on Days 0, 14, 90, and 104 in the VMDN-003 study
- Were in follow-up for the VMDN-003 study or had completed Day 270 within the last 90 days prior to signing consent
- Were using an investigational drug or treatment
- Were unable or unwilling to give informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Subjects who received Engensis (VM202) Long-Term Follow-Up of Patients who Received Engensis (VM202) VM202, Engensis Subjects who received Placebo Long-Term Follow-Up of Patients who Received Placebo Placebo, vehicle
- Primary Outcome Measures
Name Time Method Long-term Safety for Engensis Versus Placebo Baseline through Day 365 Long-term (6 months) safety in terms of the incidence of Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events for Subjects who received Engensis or Placebo (in the prior VMDN-003 study)
- Secondary Outcome Measures
Name Time Method The Change in the Average 24-hour Pain Score From Baseline (Day 0 of Study VMDN-003) to Day 365 for Engensis Versus Placebo Baseline to the Day 365 The Average 24-hour Pain Score was obtained from the Daily Pain and Sleep Interference Diary. The change in the Average 24-hour Pain Score was determined from baseline (Day 0 of Study VMDN-003) to the Day 365 visit. The Average 24-hour Pain Score is an 11-point numerical scale with scores from 0 (No Pain) to 10 (Worst Possible Pain).
Change in the Average 24-hour Pain Score From Day 270 to Day 365 for Engensis Versus Placebo Day 270 to Day 365 The Average 24-hour Pain Score is from the Daily Pain and Sleep Interference Diary. The change in the Average 24-hour Pain Score was determined for Day 270 to Day 365. The Average 24-hour Pain Score is an 11-point numerical scale with scores from 0 (No Pain) to 10 (Worst Possible Pain).
Subgroup Analysis of the Change in the Average 24-hour Pain Score From Baseline (Day 0 of Study VMDN-003) to Day 365 for Engensis Versus Placebo for Subjects Without Gabapentin and/or Pregabalin Use at Baseline Baseline to Day 365 The Average 24-hour Pain Score was obtained from the Daily Pain and Sleep Interference Diary and the change in the Average 24-hour Pain Score from baseline (Day 0 of Study VMDN-003) to the Day 365 follow-up was determined. The Average 24-hour Pain Score is an 11-point numerical scale with scores from 0 (No Pain) to 10 (Worst Possible Pain).
Patient's Global Impression of Change at the Day 365 Visit for Engensis Versus Placebo At the Day 365 visit The Patient's Global Impression of Change was completed by subjects (self-administered) at the Day 365 visit. The subject evaluated how his/her overall status had changed since the start of the study using a 7-point Patient's Global Impression of Change questionnaire scale, where 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse.
The Outcome Measure was the Patient's Global Impression of Change Categories of Scores as follows: 1 = Very Much Improved or Much Improved, 0 = Minimally Improved/Worsened or No Change, and -1 = Much Worse or Very Much Worse.
Trial Locations
- Locations (14)
Neurological Research Institute
🇺🇸Santa Monica, California, United States
University of Florida McKnight Brain Institute
🇺🇸Gainesville, Florida, United States
Diablo Clinical Research, Inc.
🇺🇸Walnut Creek, California, United States
Arizona Research Center
🇺🇸Phoenix, Arizona, United States
Center for Clinical Research
🇺🇸San Francisco, California, United States
The Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Nerve and Muscle Center of Texas
🇺🇸Houston, Texas, United States
Northern California Research
🇺🇸Sacramento, California, United States
Clinical Trials, Inc.
🇺🇸Little Rock, Arkansas, United States
EVMS (Eastern Virginia Medical School)
🇺🇸Norfolk, Virginia, United States
Innovative Research of West Florida
🇺🇸Clearwater, Florida, United States
Clinical Research of West Florida
🇺🇸Tampa, Florida, United States
Raleigh Neurology Associates, P.A.
🇺🇸Raleigh, North Carolina, United States
Rainier Clinical Research Center, Inc.
🇺🇸Renton, Washington, United States